OncoMatch/Clinical Trials/NCT06992232
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
Is NCT06992232 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Intense androgen deprivation therapy for prostate cancer metastatic disease.
Treatment: Intense androgen deprivation therapy — This multi-center randomized controlled phase II trial was carried out in several hospitals in China to evaluate the efficacy and safety of radiotherapy or radical prostatectomy combined with intense androgen deprivation therapy for newly diagnosed metastatic prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: AR testosterone non-castration range (≥50 ng/dl) or ≤3 months in castration range (testosterone ≥50 ng/dl or ≤3 months in castration range)
Non-castration range (≥50 ng/dl), or the duration of testosterone levels in the castration range is no more than 3 months
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: androgen deprivation therapy
Exception: ≤3 months
previously received androgen deprivation therapy (including medical or surgical castration) for more than 3 months
Cannot have received: focal therapy
had undergone focal therapy for prostate cancer
Cannot have received: radiation therapy
had received radiotherapy for prostate cancer
Cannot have received: cytotoxic chemotherapy
had received chemotherapy for prostate cancer
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify